CN110845559A - 新型喜树碱衍生物及其制备方法和应用 - Google Patents
新型喜树碱衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN110845559A CN110845559A CN201910752828.5A CN201910752828A CN110845559A CN 110845559 A CN110845559 A CN 110845559A CN 201910752828 A CN201910752828 A CN 201910752828A CN 110845559 A CN110845559 A CN 110845559A
- Authority
- CN
- China
- Prior art keywords
- integer
- derivative
- compound
- cancer
- camptothecin derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims description 11
- 238000000034 method Methods 0.000 claims abstract description 24
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Substances OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 230000004565 tumor cell growth Effects 0.000 claims abstract description 19
- 239000003966 growth inhibitor Substances 0.000 claims abstract description 13
- 150000003852 triazoles Chemical class 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 10
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 10
- 125000002252 acyl group Chemical group 0.000 claims abstract description 9
- 230000001093 anti-cancer Effects 0.000 claims abstract description 7
- 229920001184 polypeptide Polymers 0.000 claims abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 7
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 230000004048 modification Effects 0.000 claims abstract description 5
- 238000012986 modification Methods 0.000 claims abstract description 5
- 230000013595 glycosylation Effects 0.000 claims abstract description 4
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 46
- 238000006243 chemical reaction Methods 0.000 claims description 38
- 238000004440 column chromatography Methods 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 27
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical class C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 21
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 18
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 18
- 229960005055 sodium ascorbate Drugs 0.000 claims description 18
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 18
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 17
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 238000003786 synthesis reaction Methods 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 9
- 102000003915 DNA Topoisomerases Human genes 0.000 claims description 8
- 108090000323 DNA Topoisomerases Proteins 0.000 claims description 8
- 150000002482 oligosaccharides Polymers 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 150000001345 alkine derivatives Chemical group 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- QZBRCSFGVAKGJU-UVLRMEHCSA-N (e)-2-cyano-3-[4-[(e)-2-[4-(n-phenylanilino)phenyl]ethenyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C(C(=O)O)\C#N)=CC=C1\C=C\C1=CC=C(N(C=2C=CC=CC=2)C=2C=CC=CC=2)C=C1 QZBRCSFGVAKGJU-UVLRMEHCSA-N 0.000 claims description 2
- 101100481912 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tpc-1 gene Proteins 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- -1 azide compound Chemical class 0.000 claims description 2
- 238000012650 click reaction Methods 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 125000001483 monosaccharide substituent group Chemical group 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000001279 glycosylating effect Effects 0.000 claims 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 abstract description 18
- 229960000779 irinotecan hydrochloride Drugs 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 54
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- 238000005160 1H NMR spectroscopy Methods 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 15
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- 230000008859 change Effects 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 8
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 229940127093 camptothecin Drugs 0.000 description 6
- 230000005917 in vivo anti-tumor Effects 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 150000002772 monosaccharides Chemical group 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 4
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940125878 compound 36 Drugs 0.000 description 3
- 229940126540 compound 41 Drugs 0.000 description 3
- 229940125844 compound 46 Drugs 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 2
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 2
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 2
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 2
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 2
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 2
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 2
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 2
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 229940127113 compound 57 Drugs 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- 229940126179 compound 72 Drugs 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- FBDOJYYTMIHHDH-OZBJMMHXSA-N (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-2,4,6,8,10,14,20-heptaen-18-one Chemical compound CC[C@@]1(O)C(=O)OCC2=CN3Cc4cc5ccccc5nc4C3C=C12 FBDOJYYTMIHHDH-OZBJMMHXSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 1
- 241000759905 Camptotheca acuminata Species 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 belotecan Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003684 drug solvent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VMFMUJZRXZXYAH-UHFFFAOYSA-N n-[5-[[5-chloro-4-[2-[2-(dimethylamino)-2-oxoacetyl]anilino]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound C=CC(=O)NC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)C(=O)C(=O)N(C)C)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C)CC1 VMFMUJZRXZXYAH-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C07H11/04—Phosphates; Phosphites; Polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及新型喜树碱衍生物及其应用、肿瘤细胞生长抑制剂和三元复合物以及提高喜树碱衍生物溶解性的方法。所述的喜树碱衍生物由式1所示的物质经糖基化三氮唑在R3位置修饰而成;所述式1所示的结构式中R1代表H、C1‑10的烷基、C1‑10的氘代烷基或C1‑C10的卤代烷基;R2代表H、CH2N(CH3)2或CH2N(CD3)2;R4代表或H,其中X代表N,O或S;L代表多肽、C1‑20直链烷基或其衍生物、C1‑20直链或支链酰基衍生物、C2‑100乙二醇或其衍生物。所述喜树碱衍生物溶解度较高,制备的抗癌药物具有抗癌谱广、安全性高的优点,体内抗癌活性优于盐酸伊立替康。
Description
技术领域
本发明涉及新型喜树碱衍生物及其应用、肿瘤细胞生长抑制剂和三元复合物以及提高喜树碱衍生物溶解性的方法。所述喜树碱衍生物可制备抗肿瘤药物。
背景技术
喜树碱(Camptothecin,CPT)是最早由美国化学家Wall等于1966年从中国珙桐科植物喜树的皮、果实中提取出来的一种含有喹啉环的生物碱。早期研究发现CPT具有抗肿瘤的活性,但是,CPT在水中很差的溶解性却大大降低了其临床应用价值,之后,科学家虽然通过成盐的方法水解其分子中的酯环,增加了水溶性,但却伴随着其抗肿瘤活性的下降。此外,CPT自身有较强的副作用,如出血性膀胱炎,严重的骨髓抑制等。由于以上缺陷,20世纪70年代,科学家不得不停止CPT的临床研究。1985年,Hsiang等人发现CPT是拓扑异构酶I(ToPoI)的专属抑制剂,才使CPT的研究重获新生。国内外研究者在对其药理机制和构效关系研究的基础上,开发出一系列的喜树碱衍生物。盐酸伊立替康(Irinotecanhydrochloride,CPT-11)是一种水溶性喜树碱衍生物,临床上常用于治疗结直肠癌、肺癌和乳腺癌等,但其抗肿瘤活性依旧不高,且副作用大。开发各类喜树碱衍生物并提升其药用性能是肿瘤药物开发的挑战。
拓扑替康、贝洛替康、10-羟基喜树碱等喜树碱衍生物陆续被开发并运用于人体,但上述衍生物与人体的“兼容性”一直是制药界的重大挑战。比如,SN-38作为伊立替康的代谢产物,体外抗肿瘤活性是伊立替康的100~1000倍,但其溶解度极差,几乎不溶于常用的药物溶剂和水,因此成药性差(Santi等,J Med Chem.2014,57(6):2303-2314),在临床上应用具有很大的局限性。
发明内容
有鉴于此,本发明的目的之一在于提供了一种喜树碱衍生物,其具有较高的水溶性。
为了实现上述目的,本发明采用以下方案:
所述的喜树碱衍生物由式1所示的物质经糖基化三氮唑在R3位置修饰而成;所述式1所示的结构式中R1代表H、C1-10的烷基、C1-10的氘代烷基或C1-C10的卤代烷基;R2代表H、CH2N(CH3)2或CH2N(CD3)2;R4代表或H,其中X代表N,O或S;L代表多肽、C1-20直链烷基或其衍生物、C1-20直链或支链酰基衍生物、C2-100乙二醇或其衍生物,
进一步,所述式I中,所述R3代表或H,所述R4代表或H,但所述R3和R4不同时为H;所述R5代表单糖残基或寡糖残基;L代表多肽、C1-C20直链烷基或其衍生物、C1-C20直链或支链酰基衍生物、C1-C20乙二醇或其衍生物、或其中Y为或a为0-100的整数;b为1-100的整数;c为0-100的整数;d为0-100的整数。
进一步,所述式I中的所述R1代表H或-CH2CH3;所述R2代表H、-CH2N(CH3)2或—CH2N(CD3)2;所述R3代表或H,所述R4代表或H,但所述R3和R4不同时为H;所述R5选自单糖残基或寡糖残基;X选自N或O;L选自C1-20直链或支链烷烃及其衍生物、C1-20直链或支链酰基衍生物、C2-100乙二醇及其衍生物、或其中Y为或a为0-100的整数;b为1-100的整数;c为0-100的整数;d为0-100的整数。
进一步,所述a为0、2、4、6、8、10、12、14、16、18、20、30、40、50、60、70、80、90、100。
进一步,所述b为1、2、4、6、8、10、12、14、16、18、20、30、40、50、60、70、80、90、100。
进一步,所述c为0、2、4、6、8、10、12、14、16、18、20、30、40、50、60、70、80、90、100。
进一步,所述d为0、2、4、6、8、10、12、14、16、18、20、30、40、50、60、70、80、90、100。
进一步,所述R1代表-CH2CH3;所述R2代表H;所述R3代表所述R4代表H;所述X代表N或O;所述L代表或其中所述Y为或所述a为1-20的整数,b为1-20的整数,c为0-20的整数,d为0-20的整数。
进一步,所述的喜树碱衍生物为7-乙基-10-羟基喜树碱的衍生物,其结构式如式II所示,
进一步,所述R5选自式5-28的单糖残基中的任一:
进一步,所述a或所述b为1-20的整数。
进一步,所述R5选自单糖残基式5、6、18和19中的任一:
进一步,所述衍生物为下列化合物之一:
进一步,所述X选自N或O。
进一步,所述d为0-1的整数。
进一步,所述a为1,b为1-4的整数。
本发明的目的之二在于提供一种所述喜树碱衍生物的合成方法,该方法可应用到工业生产中。
为了实现上述目的,本发明采用以下方案:
所述方法包括以下步骤:
1)化学反应合成叠氮化合物;
2)化学反应合成端基炔;
3)将叠氮化合物和端基炔溶于THF-H2O中,依次加入无水硫酸铜和抗坏血酸钠进行点击反应,然后室温搅拌过夜,浓缩后柱层析分离得所述喜树碱衍生物;
优选的,Z为无或O,e为0-1。
本发明的目的之三在于提供一种提高喜树碱衍生物溶解性的方法,该方法适用于工业化运用。
为了实现上述目的,本发明采用以下方案:
所述方法为对7-乙基-10-羟基喜树碱衍生物进行糖基化三氮唑修饰,7-乙基-10-羟基喜树碱衍生物的结构式如式2所示,糖基化三氮唑在R3的位置进行修饰;所述式2所示的结构式中R3代表或H;其中X代表N,O或S;L代表多肽、C1-C20直链烷基或其衍生物、C1-C20直链或支链酰基衍生物、C1-C20乙二醇或其衍生物、或
进一步,所述R5的结构式如式5-28任一所示。
进一步,所述R5选自单糖残基式5、6、18和19中的任一。
进一步,所述a为1,b为1-4的整数。
进一步,所述d为0-1的整数。
本发明的目的之四在于提供一种肿瘤细胞生长抑制剂,该肿瘤细胞生长抑制剂具有抗癌作用。
为实现上述目的,本发明采用以下方案:
肿瘤细胞生长抑制剂,所述抑制剂由所述的喜树碱衍生物制备而成。
所述所述的喜树碱衍生物可含有药学上接受的任何载体和助剂。
进一步,所述肿瘤细胞生长抑制剂可通过和拓扑异构酶I、DNA形成三元复合物使DNA链断裂,抑制肿瘤细生长和促进肿瘤细胞凋亡。
进一步,所述肿瘤为结直肠瘤、肺瘤和乳腺瘤、肝癌、胃癌、食管癌、白血病、前列腺癌、骨肉瘤、宫颈癌、甲状腺癌、卵巢癌或胰腺癌。
本发明的目的之五在于提供一种三元复合物,其可以抑制肿瘤细胞生长。
为实现上述目的,本发明的技术方案为:
所述三元复合物由所述的肿瘤细胞生长抑制剂通过和拓扑异构酶I、DNA形成所述的三元复合物。所述三元复合物使DNA链断裂,抑制肿瘤细生长和促进肿瘤细胞凋亡。
本发明的目的之六在于提供所述喜树碱衍生物的应用,该应用为癌症治疗提供了新思路。
为实现上述目的,本发明采用以下方案:
所述的喜树碱衍生物在制备抗癌药物中的应用。
进一步,所述癌为结直肠癌、肺癌和乳腺癌、肝癌、胃癌、食管癌、白血病、前列腺癌、骨肉瘤、宫颈癌、甲状腺癌、卵巢癌或胰腺癌。
进一步,所述抗癌药物可通过和拓扑异构酶I、DNA形成三元复合物使DNA链断裂,抑制肿瘤细生长和促进肿瘤细胞凋亡以达到抗癌作用,所述肿瘤细胞为SW-480和/或HT-29和/或HCT-116和/或A549和/或H1975和/或HepG2和/或BGC-823和/或ECA-109和/或K562和/或PC3和/或143B和/或MDA-MB-231和/或Hela和/或TPC-1和/或SKOV-3和/或PANC-1。
本发明的目的之七在于提供一种制剂,该制剂可以有效的抑制肿瘤细胞的生长。
为实现上述目的,本发明的技术方案为:
所述的喜树碱衍生物制备的制剂。
进一步,所述制剂中含有药学可接受载体和/或助剂。
所述药学可接受剂型包括本发明的中药组合物以及可选的一种或多种药学上可接受的载体、稀释剂或赋形剂并在上述制备过程中合适的步骤加入。本发明所使用的术语“药学上可接受的”是指这样的化合物、原料、组合物和/或剂型,它们在合理医学判断的范围内,适用于与患者组织接触而无过度毒性、刺激性、变态反应或与合理的利益/风险比相对称的其他问题和并发症,并有效用于既定用途。
药物制剂适于通过任何合适的途径给药,例如通过口服(包括口腔或舌下)、直肠、鼻、局部(包括口腔、舌下或经皮)、阴道或胃肠外(包括皮下、皮内、肌内、关节内、滑膜内、胸骨内、鞘内、病灶内、静脉内或者真皮下注射或输注)途径。可按药剂学领域的任何已知方法制备这类制剂,例如通过将活性成分与载体或赋形剂混合。优选口服给药、局部给药或注射给药。适于口服给药的药物制剂按独立的单位提供,例如水性或非水性液体中的溶液剂或混悬剂;胶囊剂或片剂;散剂或颗粒剂;可食用泡沫制剂或起泡制剂等。
举例来说,对于以片剂或胶囊剂形式的口服给药,活性药物组分可与药学上可接受的口服无毒惰性载体(例如乙醇、甘油、水等)相混合。通过将化合物粉碎成合适的微细尺寸,并与被同样粉碎的药用载体(例如淀粉或甘露醇等可食用的糖类)混匀来制备散剂。还可存在矫味剂、防腐剂、分散剂和着色剂。通过制备如上所述的粉状混合物,并装填到成形的明胶壳内,来制备胶囊剂。在装填操作之前,可将助流剂和润滑剂(例如胶态二氧化硅、滑石粉、硬脂酸镁、硬脂酸钙或固态聚乙二醇)加到粉状混合物中。还可加入当服下胶囊剂时将改进药物可利用性的崩解剂或增溶剂(例如琼脂、碳酸钙或碳酸钠)。
此外需要或必需时,也可将合适的粘合剂、润滑剂、崩解剂和着色剂掺到混合物中。合适的粘合剂包括淀粉、明胶、天然糖(例如葡萄糖或β-乳糖)、玉米甜味剂、天然和合成树胶(例如阿拉伯树胶、西黄蓍胶或藻酸钠)、羧甲基纤维素、聚乙二醇等。用于这些剂型的润滑剂包括油酸钠、氯化钠等。
崩解剂包括但并不限于淀粉、甲基纤维素、琼脂、皂土、黄原胶等。例如,通过制成粉状混合物,制粒或预压片,加入润滑剂和崩解剂,压制成片,从而制成片剂。将适当粉碎的化合物与如上述所述的稀释剂或基料、任选与粘合剂(例如羧甲基纤维素、藻酸盐、明胶或聚乙烯吡咯烷酮)、溶解阻止剂(例如石蜡)、吸收加速剂(季盐)和/或吸收剂(例如皂土、高岭土或磷酸二钙)混合,来制备粉状混合物。可用粘合剂(例如糖浆、淀粉浆、阿拉伯胶浆或纤维素材料或聚合材料溶液)润湿后加压过筛,将粉状混合物制粒。制粒的一个替代方法是,可将粉状混合物通过压片机,结果是将形成不佳的团块再击碎制成颗粒。可通过加入硬脂酸、硬脂酸盐,滑石粉或矿物油使颗粒润滑以防止粘到压片机的冲模上。然后将经润滑的混合物压制成片。本发明内容的化合物还可与自由流动的惰性载体混合,无需通过制粒或预压片步骤便可压制成片。可提供透明或不透明的由虫胶密封衣、糖衣或聚合材料衣和蜡质抛光衣组成的保护性包衣材料。可将染料加到这些包衣材料中以区分不同的单位剂量。
口服液体制剂例如溶液剂、糖浆剂和酏剂可以剂量单位形式制备,从而给定量含有预定量的化合物。糖浆剂可通过将化合物溶于适当调味的水溶液中来制备,而酏剂可通过使用无毒溶媒来制备。还可加入防腐剂、矫味添加剂(例如薄荷油或天然甜味剂或糖精或其他人造甜味剂)等。
适于经皮给药的药物制剂可作为离散的贴剂以在长时间内保持与接受者表皮密切接触。例如,活性成分可由通过离子导入贴剂递药,通常可参见PharmaceuticalResearch,1986,3(6),318。
适于局部给药的药物制剂可制成软膏剂、乳膏剂、混悬剂、洗剂、散剂、溶液剂、糊剂、凝胶剂、喷雾剂、气雾剂、油制剂或透皮贴剂。适于经鼻给药的药物制剂(其中载体为固体)包括粒径为例如20-500微米范围的粗粉剂,通过以鼻吸方式给药,即通过鼻通道从接近鼻子的粗粉剂容器中快速吸入。其中载体为液体、适于作为鼻腔喷雾剂或滴鼻剂给药的合适制剂包括活性成分的水性溶液剂或油性溶液剂。
适于通过吸入给药的药物制剂包括微细粒子粉剂或细雾剂,可用不同类型计量的剂量压缩气溶胶、雾化吸入器、吹入器或其他事宜递送气溶胶喷雾剂的装置中制备。适于胃肠外给药的药物制剂包括水性和非水性无菌注射溶液剂及水性和非水性无菌混悬剂,水性和非水性无菌注射溶液剂可含有抗氧化剂、缓冲剂、抑菌剂和使所述制剂与待接受者血液等渗的溶质。制剂可以单位剂量或多剂量容器提供,例如密封的安凯和小瓶,并可保存在冷冻干燥(冻干)条件下,只需在临用前加入无菌液体载体,例如注射用水。临用时配置的注射溶液剂可由无菌粉针剂、颗粒剂和片剂制备。
药物制剂可呈单位剂型,每个单位剂量含有预定量的活性成分。给药法可用作长期或短期疗法。与载体材料混合以制备单一剂型的活性成分的量将根据待治疗的疾病、疾病的严重程度、给药时间、给药途径、所用化合物的排泄速率、治疗时间和患者年龄、性别、体重和情况而改变。优选的单位剂型是含有上述活性成分的日剂量或分剂量或其适宜分数的单位剂型。可用显然低于化合物最佳剂量的小剂量开始治疗。此后,以较小的增量来加大剂量直到在这种情况下达到最佳效果。一般而言,最理想地给予化合物的浓度水平是通常可在抗病毒方面提供有效结果而又不至于引起任何有害或有毒的副作用。
本发明有益效果:
1)本发明提供了新型的喜树碱衍生物,且溶解度显著比SN38高;
2)本发明所述的肿瘤细胞生长抑制剂和制备的抗癌药物抗癌谱广,抗癌活性优于盐酸伊立替康;
3)所述肿瘤细胞生长抑制剂和制备的抗癌药物用药安全性高,高剂量使用也没有明显副作用产生。
附图说明
图1:裸鼠肿瘤体积-时间变化图;
图2:裸鼠体重-时间变化图。
图3:多剂量化合物体内抗肿瘤活性研究中化合物58裸鼠肿瘤体积-时间变化图。
图4:多剂量化合物体内抗肿瘤活性研究中化合物67裸鼠肿瘤体积-时间变化图。
图5:多剂量化合物体内抗肿瘤活性研究中体重时间变化图。
具体实施方式
下面通过具体实施例进一步说明本发明,但是,应当理解为,这些实施例仅仅是用于更详细的具体说明用,而不应理解为用于以任何形式限制本发明。
本发明对试验中所使用到的材料以及实验方法进行一般性和具体性的描述。虽然为实现本发明的目的所使用的许多材料和操作方法是本领域公知的,但是本发明仍然在此作尽可能详细的描述。本领域技术人员清楚,在下文中,如未特别说明,所使用的材料和操作方法是本领域公知的。
实施例1化合物37的合成
称量9g化合物29溶于60mL二氯甲烷中,加入25mL 33%氢溴酸的醋酸溶液,室温反应2小时,TLC监测反应完全,倒入50mL水中,二氯甲烷萃取(50mL×3),合并有机层并用饱和碳酸氢钠洗涤一次,无水硫酸钠干燥,过滤,浓缩后,用石油醚/乙酸乙酯10/1的混合溶剂重结晶后得到8.2g化合物30,收率86.7%。通过核磁共振氢谱,鉴定化合物结构。
1H NMR(400Hz,CDCl3)δ6.61(d,J=4.4Hz,1H),5.56(t,J=9.6Hz,1H),5.16(t,J=9.8Hz,1H),4.84(dd,J=10.0,4.0Hz,1H),4.28-4.35(m,2H),4.12-4.15(m,1H),2.10(s,3H),2.09(s,3H),2.05(s,3H),2.04(s,3H)。
将8.2g化合物30溶于40mL干燥的DMSO中,加入1.56g叠氮化钠,室温搅拌1小时,TLC监测反应完全,倒入100mL水中,乙酸乙酯萃取(50mL×3),合并有机层并用无水硫酸钠干燥,过滤,浓缩后,用石油醚/乙酸乙酯10/1的混合溶剂重结晶后得到5.8g化合物31,收率77.7%。
1H NMR(400Hz,CDCl3)δ5.22(t,J=9.4Hz,1H),5.11(t,J=9.6Hz,1H),4.96(t,J=9.2Hz,1H),4.65(d,J=8.8Hz,1H),4.26-4.30(m,1H),4.16-4.19(m,1H),3.78-3.82(m,1H),2.11(s,3H),2.08(s,3H),2.03(s,3H),2.01(s,3H)。
称量1g化合物31溶于5mL无水甲醇中,加入10mL 0.5N NaOMe-MeOH溶液,室温搅拌过夜,加入适量的强酸性阳离子交换树脂,继续搅拌15分钟,测量体系中pH为中性或弱酸性,过滤,滤液浓缩后得到420mg化合物32,收率76.4%。
1H NMR(400Hz,D2O)δ4.68(d,J=8.8Hz,1H),3.84-3.88(m,1H),3.66-3.71(m,1H),3.46-3.48(m,2H),3.29-3.38(m,1H),3.21(t,J=9.0Hz,1H)。
将23mL乙二醇(化合物33)溶于100mL干燥的四氢呋喃中,冷却至0℃,分小批量加入5.5g氢化钠,加入完毕后,继续在此温度下反应2小时。称量10g 3-溴丙炔溶于30mL干燥的四氢呋喃中,并缓慢的滴加至上述反应中,完毕后室温反应过夜。向反应体系中加入20mL水,浓缩掉四氢呋喃,乙酸乙酯萃取(40mL×3),合并有机层,无水硫酸钠干燥,过滤,浓缩后柱层析得5.5g化合物34,收率64.9%。
1H NMR(400Hz,DMSO-d6)δ4.64(t,J=5.6Hz,1H),4.14(d,J=2.4Hz,2H),3.49-3.52(m,2H),3.44-3.47(m,2H),3.88(t,J=2.4Hz,1H)。
称量1g化合物34溶于50mL二氯甲烷中,加入2g三乙胺和3g对硝基苯基氯甲酸酯,室温搅拌过夜,浓缩后柱层析得1g化合物35,收率37.7%。
称量392mg SN38溶于20mL 1:1 DCM-DMF的混合溶剂中,依次加入200mg三乙胺和310mg化合物35,室温搅拌过夜,减压真空浓缩,柱层析得300mg化合物36,收率57.9%。
1H NMR(400Hz,DMSO-d6)δ8.22(d,J=9.2Hz,1H),8.16(d,J=2.8Hz,1H),7.78(dd,J=9.2,2.4Hz,1H),7.34(s,1H),6.52(s,1H),5.44(s,2H),5.34(s,2H),4.41-4.43(m,2H),4.24(d,J=2.4Hz,2H),3.77-3.79(m,2H),3.51(t,J=2.4Hz,1H),3.18-3.21(m,2H),1.85-1.90(m,2H),1.30(t,J=7.6Hz,3H),0.89(t,J=7.4Hz,3H)。
将157mg化合物36和63mg化合物32溶于10mL 1:1 THF-H2O中,依次加入25mg无水硫酸铜和30mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到135mg化合物37,收率61.6%。
1H NMR(400Hz,DMSO-d6)δ8.34(s,1H),8.23(d,J=9.2Hz,1H),8.17(d,J=2.4Hz,1H),7.77(dd,J=9.2,2.8Hz,1H),7.34(s,1H),6.52(s,1H),5.55(d,J=9.2Hz,1H),5.44(s,2H),5.38(d,J=6.0Hz,1H),5.34(s,2H),5.27(d,J=4.8Hz,1H),5.14(d,J=5.6Hz,1H),4.62-4.63(m,3H),4.41-4.44(m,2H),3.69-3.82(m,4H),3.40-3.46(m,3H),3.19-3.24(m,3H),1.86-1.89(m,2H),1.29(t,J=7.6Hz,3H),0.88(t,J=7.2Hz,3H)。
实施例2化合物42的合成
将80mL四甘醇(化合物38)溶于200mL干燥的四氢呋喃中,冷却至0℃,分小批量加入5.5g氢化钠,加入完毕后,继续在此温度下反应2小时。称量10g 3-溴丙炔溶于30mL干燥的四氢呋喃中,并缓慢的滴加至上述反应中,完毕后室温反应过夜。向反应体系中加入20mL水,浓缩掉四氢呋喃,乙酸乙酯萃取(60mL×3),合并有机层,无水硫酸钠干燥,过滤,浓缩后柱层析得11.7g化合物39,收率59.5%。
1H NMR(400Hz,CDCl3)δ4.20-4.24(m,2H),3.67-3.71(m,14H),3.60-3.62(m,2H),2.46(t,J=2.4Hz,1H)。
称量1g化合物39溶于50mL二氯甲烷中,加入870mg三乙胺和1.3g对硝基苯基氯甲酸酯,室温搅拌过夜,浓缩后柱层析得600mg化合物40,收率35.1%。
称量392mg SN38溶于20mL 1:1 DCM-DMF的混合溶剂中,依次加入200mg三乙胺和397mg化合物40,室温搅拌过夜,减压真空浓缩,柱层析得391mg化合物41,收率60.3%。
1H NMR(400Hz,DMSO-d6)δ8.22(d,J=9.2Hz,1H),8.16(d,J=2.4Hz,1H),7.78(dd,J=9.2,2.8Hz,1H),7.34(s,1H),6.52(s,1H),5.44(s,2H),5.33(s,2H),4.38-4.41(m,2H),4.14(d,J=2.4Hz,2H),3.73-3.76(m,2H),3.51-3.57(m,12H),3.40(t,J=2.4Hz,1H),3.18-3.21(m,2H),1.86-1.90(m,2H),1.30(t,J=7.6Hz,3H),0.89(t,J=7.4Hz,3H)。
将160mg化合物41和65mg化合物32溶于10mL 1:1 THF-H2O中,依次加入20mg无水硫酸铜和24mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到60mg化合物42,收率28.5%。
1H NMR(400Hz,DMSO-d6)δ8.27(s,1H),8.23(d,J=9.2Hz,1H),8.17(d,J=2.8Hz,1H),7.78(dd,J=9.2,2.8Hz,1H),7.34(s,1H),6.52(s,1H),5.51(d,J=9.6Hz,1H),5.44(s,2H),5.36(d,J=6.0Hz,1H),5.34(s,2H),5.26(d,J=4.8Hz,1H),5.13(d,J=5.6Hz,1H),4.62(t,J=5.6Hz,1H),4.53(s,2H),4.38-4.40(m,2H),3.72-3.76(m,4H),3.53-3.57(m,10H),3.42-3.46(m,2H),3.18-3.28(m,4H),1.84-1.90(m,4H),1.29(t,J=7.6Hz,3H),0.87(t,J=7.6Hz,3H)。
实施例3化合物47的合成
将46mL二甘醇(化合物43)溶于100mL干燥的四氢呋喃中,冷却至0℃,分小批量加入5.5g氢化钠,加入完毕后,继续在此温度下反应2小时。称量10g 3-溴丙炔溶于30mL干燥的四氢呋喃中,并缓慢的滴加至上述反应中,完毕后室温反应过夜。向反应体系中加入20mL水,浓缩掉四氢呋喃,乙酸乙酯萃取(50mL×3),合并有机层,无水硫酸钠干燥,过滤,浓缩后柱层析得5.53g化合物44,收率45.3%。
1H NMR(400Hz,DMSO-d6)δ4.56(t,J=5.6Hz,1H),4.14(d,J=2.4Hz,2H),3.51-3.59(m,4H),3.46-3.49(m,2H),3.40-3.44(m,3H)。
称量1g化合物44溶于50mL二氯甲烷中,加入1.4g三乙胺和2.1g对硝基苯基氯甲酸酯,室温搅拌过夜,浓缩后柱层析得603mg化合物45,收率28.1%。
1H NMR(400Hz,DMSO-d6)δ7.56-7.58(m,2H),6.91-6.95(m,2H),4.37-4.39(m,2H),4.16(d,J=2.4Hz,2H),3.70-3.72(m,2H),3.59-3.62(m,4H),3.42(t,J=2.4Hz,1H)。
称量392mg SN38溶于20mL 1:1 DCM-DMF的混合溶剂中,依次加入200mg三乙胺和309mg化合物45,室温搅拌过夜,减压真空浓缩,柱层析得357mg化合物46,收率63.6%。
1H NMR(400Hz,DMSO-d6)δ8.23(d,J=9.2Hz,1H),8.16(d,J=2.4Hz,1H),7.78(dd,J=9.2,2.8Hz,1H),7.34(s,1H),6.52(s,1H),5.44(s,2H),5.34(s,2H),4.38-4.41(m,2H),4.18(d,J=2.4Hz,2H),3.72-3.75(m,2H),3.60-3.62(m,4H),3.44(t,J=2.4Hz,1H),3.18-3.21(m,2H),1.86-1.90(m,2H),1.30(t,J=7.6Hz,3H),0.89(t,J=7.4Hz,3H)。
将95mg化合物46和35mg化合物32溶于10mL 1:1 THF-H2O中,依次加入27mg无水硫酸铜和33mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到80mg化合物47,收率61.6%。
1H NMR(400Hz,DMSO-d6)δ8.31(s,1H),8.22(d,J=9.2Hz,1H),8.17(d,J=3.0Hz,1H),7.78(dd,J=9.2,2.8Hz,1H),7.34(s,1H),6.52(s,1H),5.53(d,J=9.2Hz,1H),5.44(s,2H),5.13-5.33(m,5H),4.57-4.63(m,3H),4.38-4.40(m,2H),3.67-3.79(m,4H),3.64(s,4H),3.37-3.45(m,3H),3.17-3.25(m,3H),1.82-1.91(m,2H),1.29(t,J=7.6Hz,3H),0.89(t,J=7.6Hz,3H)。
实施例4化合物52的合成
将69mL三甘醇(化合物48)溶于150mL干燥的四氢呋喃中,冷却至0℃,分小批量加入5.5g氢化钠,加入完毕后,继续在此温度下反应2小时。称量10g 3-溴丙炔溶于30mL干燥的四氢呋喃中,并缓慢的滴加至上述反应中,完毕后室温反应过夜。向反应体系中加入20mL水,浓缩掉四氢呋喃,乙酸乙酯萃取(50mL×3),合并有机层,无水硫酸钠干燥,过滤,浓缩后柱层析得7.6g化合物49,收率47.8%。
1H NMR(400Hz,DMSO-d6)δ4.54(t,J=5.4Hz,1H),4.14(d,J=2.4Hz,2H),3.47-3.53(m,10H),3.36-3.43(m,3H)。
称量1g化合物49溶于50mL二氯甲烷中,加入1.1g三乙胺和1.6g对硝基苯基氯甲酸酯,室温搅拌过夜,浓缩后柱层析得685mg化合物50,收率36.5%。
称量392mg SN38溶于20mL 1:1 DCM-DMF的混合溶剂中,依次加入200mg三乙胺和353mg化合物50,室温搅拌过夜,减压真空浓缩,柱层析得375mg化合物51,收率61.9%。
1H NMR(400Hz,DMSO-d6)δ8.22(d,J=9.2Hz,1H),8.16(d,J=2.4Hz,1H),7.78(dd,J=9.2,2.4Hz,1H),7.34(s,1H),6.52(s,1H),5.44(s,2H),5.34(s,2H),4.38-4.41(m,2H),4.15(d,J=2.4Hz,2H),3.73-3.75(m,2H),3.56-3.62(m,8H),3.41(t,J=2.4Hz,1H),3.17-3.23(m,2H),1.84-1.91(m,2H),1.30(t,J=7.6Hz,3H),0.89(t,J=7.4Hz,3H)。
将146mg化合物51和50mg化合物32溶于10mL 1:1 THF-H2O中,依次加入39mg无水硫酸铜和48mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到75mg化合物52,收率38.5%。
1H NMR(400Hz,DMSO-d6)δ8.29(s,1H),8.19(d,J=9.2Hz,1H),8.17(d,J=2.8Hz,1H),7.78(dd,J=9.2,2.8Hz,1H),7.34(s,1H),6.52(s,1H),5.52(d,J=9.6Hz,1H),5.44(s,2H),5.36(d,J=6.0Hz,1H),5.34(s,2H),5.26(d,J=4.8Hz,1H),5.13(d,J=5.6Hz,1H),4.62(t,J=5.6Hz,1H),4.55(s,2H),4.38-4.40(m,2H),3.67-3.77(m,4H),3.56-3.61(m,8H),3.36-3.46(m,3H),3.16-3.24(m,3H),1.86-1.90(m,2H),1.30(t,J=7.2Hz,3H),0.89(t,J=7.2Hz,3H)。
实施例5化合物56的合成
称量18g化合物29溶于150mL二氯甲烷,加入6.3g溴乙醇和8.7mL三氟化硼乙醚,室温反应过夜。加入饱和碳酸氢钠直至没有气体产生,用DCM萃取三次,有机层合并干燥,浓缩,柱层析得到10g化合物53,收率47.7%。
1H NMR(400Hz,CDCl3)δ5.25(t,J=9.6Hz,1H),4.87-4.93(m,2H),4.77-4.81(m,1H),4.15-4.20(m,1H),3.96-4.00(m,2H),3.77-3.82(m,1H),3.55-3.62(m,2H),2.02(s,3H),2.00(s,3H),1.98(s,3H),1.94(s,3H)。
称量10g化合物53溶于150mLDMF中,加入2.86g叠氮化钠。60℃反应过夜。TLC监测反应完全。冷却至室温,加入适量的水,乙酸乙酯萃取两次(100mL×3),浓缩掉有几层和残留的少量DMF,加入适量乙醇析出固体,过滤得到6.9g产物54,收率75.2%。
1H NMR(400Hz,CDCl3)δ5.22(t,J=9.4Hz,1H),5.10(t,J=9.6Hz,1H),5.00-5.04(m,1H),4.60(d,J=8.0Hz,1H),4.24-4.28(m,1H),4.14-4.17(m,1H),4.02-4.05(m,1H),3.67-3.74(m,2H),3.46-3.53(m,1H),3.27-3.32(m,1H),2.09(s,3H),2.05(s,3H),2.03(s,3H),2.01(s,3H)。
称量1g化合物54溶于5mL无水甲醇中,加入10mL 0.5N NaOMe-MeOH溶液,室温搅拌过夜,加入适量的强酸性阳离子交换树脂,继续搅拌15分钟,测量体系中pH为中性或弱酸性,过滤,滤液浓缩后得到430mg化合物55,收率72.0%。
1H NMR(400Hz,D2O)δ4.44(d,J=8.0Hz,1H),3.97-4.02(m,1H),3.84-3.88(m,1H),3.76-3.80(m,1H),3.64-3.69(m,1H),3.38-3.51(m,4H),3.29-3.35(m,1H),3.24(t,J=8.0Hz,1H)。
将170mg化合物36和82mg化合物55溶于16mL THF-H2O中,依次加入26mg无水硫酸铜和33mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到110mg化合物56,收率43.8%。
1H NMR(400Hz,DMSO-d6)δ8.22(d,J=9.2Hz,1H),8.20(s,1H),8.17(d,J=3.0Hz,1H),7.78(dd,J=9.2,3.0Hz,1H),7.34(s,1H),6.52(s,1H),5.44(s,2H),5.34(s,2H),4.91-5.01(m,3H),4.57-4.61(m,4H),4.40-4.42(m,2H),4.24(d,J=8.0Hz,1H),4.07-4.11(m,1H),3.89-3.95(m,1H),3.78-3.80(m,2H),3.68(d,J=5.6Hz,1H),3.42-3.46(m,1H),2.96-3.17(m,7H),1.82-1.91(m,2H),1.31(t,J=7.4Hz,3H),0.89(t,J=7.4Hz,3H)。
实施例6化合物57的合成
将80mg化合物46和36mg化合物55溶于14mL THF-H2O中,依次加入23mg无水硫酸铜和28mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到50mg化合物57,收率43.3%。
1H NMR(400Hz,DMSO-d6)δ8.22(d,J=9.2Hz,1H),8.16(s,2H),7.78(dd,J=9.2,2.4Hz,1H),7.34(s,1H),6.52(s,1H),5.44(s,2H),5.34(s,2H),5.07(d,J=4.8Hz,1H),4.93(dd,J=12.8,4.8Hz,2H),4.49-4.57(m,5H),4.39(t,J=4.4Hz,2H),4.23(d,J=7.6Hz,1H),4.07-4.10(m,1H),3.89-3.92(m,1H),3.62-3.75(m,7H),3.42-3.45(m,1H),3.10-3.19(m,4H),2.97-3.05(m,2H),1.86-1.90(m,2H),1.30(t,J=7.6Hz,3H),0.89(t,J=7.2Hz,3H)。
实施例7化合物58的合成
将98mg化合物51和40mg化合物55溶于14mL THF-H2O中,依次加入26mg无水硫酸铜和32mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到65mg化合物58,收率48.5%。
1H NMR(400Hz,DMSO-d6)δ8.22(d,J=9.2Hz,1H),8.16(d,J=2.4Hz,1H),8.15(s,1H),7.78(dd,J=9.2,2.4Hz,1H),7.34(s,1H),6.52(s,1H),5.44(s,2H),5.34(s,2H),5.07(d,J=3.2Hz,1H),4.92(dd,J=12.8,4.8Hz,2H),4.49-4.58(m,5H),4.38-4.39(m,2H),4.22(d,J=8.0Hz,1H),4.07-4.09(m,1H),3.89-3.92(m,1H),3.73-3.75(m,2H),3.65-3.69(m,1H),3.56-3.61(m,8H),3.42-3.45(m,1H),3.10-3.18(m,4H),2.96-3.05(m,2H),1.86-1.90(m,2H),1.30(t,J=7.6Hz,3H),0.89(t,J=7.2Hz,3H)。
实施例8化合物59的合成
将316mg化合物41和121mg化合物55溶于16mL THF-H2O中,依次加入78mg无水硫酸铜和96mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到100mg化合物59,收率22.9%。
1H NMR(400Hz,DMSO-d6)δ8.23(d,J=9.2Hz,1H),8.16(s,1H),8.14(s,1H),7.78(d,J=9.2Hz,1H),7.34(s,1H),6.52(s,1H),5.44(s,2H),5.34(s,2H),5.06(d,J=4.8Hz,1H),4.92(dd,J=12.8,4.8Hz,2H),4.51-4.56(m,5H),4.39(s,2H),4.22(d,J=7.6Hz,1H),4.06-4.09(m,1H),3.89-3.91(m,1H),3.66-3.74(m,3H),3.53-3.55(m,11H),3.37-3.44(m,1H),3.13-3.18(m,5H),2.96-3.04(m,2H),1.86-1.90(m,2H),1.30(t,J=7.2Hz,3H),0.89(t,J=6.8Hz,3H)。
实施例9化合物66的合成
称量5g化合物60和16.6g三乙胺溶于150mL二氯甲烷中,冷却至0℃,缓慢的滴加11.8g二碳酸二叔丁酯,滴加完毕后,室温反应过夜,反应液用1N HCl洗涤(100mL×3),有机层用无水硫酸钠干燥,过滤,浓缩得到5g化合物61,收率37.9%。
1H NMR(400Hz,DMSO-d6)δ6.45(s,1H),4.57(t,J=5.6Hz,1H),3.33-3.38(m,2H),2.95-2.99(m,2H),1.37(s,9H)。
称量2g化合物61溶于40mL四氢呋喃中,加入458mg四丁基碘化铵,280mg碘化钠和1.77g 3-溴丙炔,室温搅拌下分小批量加入7g氢氧化钾,完毕后室温反应过夜,浓缩掉四氢呋喃,加入30mL水,乙酸乙酯萃取(30mL×3),有机层用无水硫酸钠干燥,过滤,浓缩柱层析得到1.9g化合物62,收率76.9%。
称量1.8g化合物62溶于20mL甲醇中,加入20mL 3N HCl溶液,室温搅拌过夜,浓缩得到900mg化合物63,收率73.8%。
1H NMR(400Hz,D2O)δ4.22(s,2H),3.78(t,J=4.2Hz,2H),3.18(t,J=4.0Hz,2H)。
称量490mg SN38溶于30mLDMF中,冷却至0℃,加入320mg DIPEA和330mg对硝基苯基氯甲酸酯,在此温度下继续反应半小时,室温反应3小时得到中间体64,向其中加入320mgDIPEA和253mg化合物63。加入完毕后室温反应过夜,浓缩掉DMF,TLC监测反应良好。柱层析分离得到420mg粗品产物65。
将210mg化合物65和160mg化合物32于16mL THF-H2O中,依次加入124mg无水硫酸铜和153mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到60mg化合物66,两步收率13.3%。
1H NMR(400Hz,DMSO-d6)δ8.33(s,1H),8.17(d,J=8.8Hz,1H),8.04-8.05(m,1H),7.96(s,1H),7.64(d,J=9.2Hz,1H),7.33(s,1H),6.51(s,1H),5.54(d,J=9.2Hz,1H),5.44(s,2H),5.38(d,J=6.0Hz,1H),5.33(s,2H),5.28(d,J=4.8Hz,1H),5.14(d,J=5.2Hz,1H),4.60-4.62(m,3H),3.68-3.78(m,2H),3.60(t,J=5.0Hz,2H),3.37-3.46(m,4H),3.16-3.26(m,4H),1.86-1.90(m,2H),1.30(t,J=7.4Hz,3H),0.89(t,J=7.2Hz,3H)。
实施例10化合物67的合成
将210mg粗品化合物65和160mg化合物55溶于16mL THF-H2O中,依次加入124mg无水硫酸铜和153mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到60mg化合物67,收率12.5%。
1H NMR(400Hz,DMSO-d6)δ8.16-8.19(m,2H),8.01(t,J=1.6Hz,1H),7.95(d,J=2.4Hz,1H),7.64(dd,J=9.2,2.4Hz,1H),7.33(s,1H),6.51(s,1H),5.44(s,2H),5.34(s,2H),5.08(d,J=4.8Hz,1H),4.94(dd,J=14.4,4.8Hz,2H),4.50-4.58(m,5H),4.23(d,J=7.6Hz,1H),4.07-4.11(m,1H),3.90-3.93(m,1H),3.66-3.70(m,1H),3.58(t,J=5.6Hz,2H),3.41-3.46(m,2H),3.10-3.20(m,5H),2.95-3.07(m,2H),1.84-1.91(m,2H),1.30(t,J=7.4Hz,3H),0.88(t,J=7.2Hz,3H)。
实施例11化合物73的合成
称量10g化合物68和19.2g三乙胺溶于150mL二氯甲烷中,冷却至0℃,缓慢的滴加22.9g二碳酸二叔丁酯,滴加完毕后,室温反应过夜,反应液用1N HCl洗涤(100mL×3),有机层用无水硫酸钠干燥,过滤,浓缩得到7.5g化合物69,收率38.5%。
1H NMR(400Hz,DMSO-d6)δ6.75(s,1H),4.55-4.58(m,1H),3.46-3.50(m,2H),3.36-3.40(m,4H),3.05-3.09(m,2H),1.38(s,9H)。
称量2g化合物69溶于40mL四氢呋喃中,加入360mg四丁基碘化铵,220mg碘化钠和1.39g 3-溴丙炔,室温搅拌下分小批量加入5.5g氢氧化钾,完毕后室温反应过夜,浓缩掉四氢呋喃,加入30mL水,乙酸乙酯萃取(30mL×3),有机层用无水硫酸钠干燥,过滤,浓缩柱层析得到1.4g化合物70,收率59.1%。
称量1.3g化合物70溶于20mL甲醇中,加入20mL 3N HCl溶液,室温搅拌过夜,浓缩得到600mg化合物71,收率62.7%。
1H NMR(400Hz,D2O)δ4.21(d,J=2.4Hz,2H),3.68-3.74(m,6H),3.16-3.18(m,2H),2.87(t,J=2.2Hz,1H)。
称量490mg SN38溶于30mLDMF中,冷却至0℃,加入320mg DIPEA和251mg对硝基苯基氯甲酸酯,在此温度下继续反应半小时,室温反应3小时后得到中间体64,向其中加入320mg DIPEA和269mg化合物71。加入完毕后室温反应过夜,浓缩掉DMF,TLC监测反应良好。柱层析分离得到330mg粗品产物72。将165mg化合物72和117mg化合物32溶于16mL THF-H2O中,依次加入91mg无水硫酸铜和113mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到60mg化合物73,两步收率12.5%。
1H NMR(400Hz,DMSO-d6)δ8.31(s,1H),8.18(d,J=9.2Hz,1H),7.95-8.02(m,2H),7.64(dd,J=9.2,2.0Hz,1H),7.33(s,1H),6.52(s,1H),5.53(d,J=9.2Hz,1H),5.44(s,2H),5.34-5.38(m,3H),5.27(d,J=4.8Hz,1H),5.14(d,J=5.6Hz,1H),4.63(t,J=5.6Hz,1H),4.58(s,2H),3.52-3.78(m,8H),3.36-3.45(m,4H),3.17-3.24(m,4H),1.86-1.90(m,2H),1.30(t,J=7.4Hz,3H),0.88(t,J=7.4Hz,3H)。
实施例12化合物74的合成
将165mg粗品化合物72和125mg化合物55溶于16mL THF-H2O中,依次加入91mg无水硫酸铜和113mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到50mg化合物74,两步收率9.9%。
1H NMR(400Hz,DMSO-d6)δ8.16-8.18(m,2H),8.00(d,J=5.6Hz,1H),7.95(s,1H),7.63(d,J=8.8Hz,1H),7.33(s,1H),6.51(s,1H),5.44(s,2H),5.33(s,2H),5.07(d,J=4.8Hz,1H),4.93(dd,J=13.2,4.4Hz,2H),4.49-4.58(m,5H),4.23(d,J=6.8Hz,1H),4.07-4.09(m,1H),3.89-3.92(m,1H),3.60-3.70(m,5H),3.53(t,J=6.0Hz,2H),3.39-3.43(m,1H),3.28-3.31(m,2H),3.10-3.20(m,4H),2.96-2.99(m,2H),1.84-1.89(m,2H),1.29(t,J=7.6Hz,3H),0.89(t,J=7.2Hz,3H)。
实施例13化合物80的合成
称量5g化合物75和13.4g三乙胺溶于150mL二氯甲烷中,冷却至0℃,缓慢的滴加14.5g二碳酸二叔丁酯,滴加完毕后,室温反应过夜,反应液用1N HCl洗涤(100mL×3),有机层用无水硫酸钠干燥,过滤,浓缩得到7g化合物76,收率60.3%。
1H NMR(400Hz,DMSO-d6)δ6.72(s,1H),4.37(t,J=9.2Hz,1H),3.36-3.41(m,2H),2.93-2.98(m,2H),1.48-1.55(m,2H),1.37(s,9H)。
称量3.5g化合物76溶于60mL四氢呋喃中,加入1.09g四丁基碘化铵,450mg碘化钠和2.85g 3-溴丙炔,室温搅拌下分小批量加入11.2g氢氧化钾,完毕后室温反应过夜,浓缩掉四氢呋喃,加入30mL水,乙酸乙酯萃取(30mL×3),有机层用无水硫酸钠干燥,过滤,浓缩柱层析得到2.4g化合物77,收率56.3%。
称量1.3g化合物77溶于20mL甲醇中,加入20mL 3N HCl溶液,室温搅拌过夜,浓缩得到620mg化合物78,收率68.2%。
称量392mg化合物SN38溶于30mLDMF中,冷却至0℃,加入320mg DIPEA和266mg对硝基苯基氯甲酸酯,在此温度下继续反应半小时,室温反应3小时后得到中间体64,然后加入320mg DIPEA和224mg化合物78。加入完毕后室温反应过夜,浓缩掉DMF,TLC监测反应良好。柱层析分离得到440mg粗品产物79。将220mg化合物79和214mg化合物32溶于16mL THF-H2O中,依次加入166mg无水硫酸铜和206mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到70mg化合物80,两步收率19.0%。
1H NMR(400Hz,DMSO-d6)δ8.30(s,1H),8.16(d,J=9.2Hz,1H),7.94-7.97(m,2H),7.64(dd,J=9.2,2.4Hz,1H),7.32(s,1H),6.51(s,1H),5.53(d,J=9.2Hz,1H),5.44(s,2H),5.37(d,J=5.6Hz,1H),5.31(s,2H),5.28(d,J=4.8Hz,1H),5.15(d,J=5.6Hz,1H),4.62(t,J=5.6Hz,1H),4.55(s,2H),3.68-3.79(m,2H),3.55-3.58(m,2H),3.37-3.41(m,3H),3.17-3.27(m,5H),1.77-1.91(m,4H),1.30(t,J=7.6Hz,3H),0.89(t,J=7.4Hz,3H)。
实施例14化合物81的合成
将220mg粗品化合物79和224mg化合物55溶于16mL THF-H2O中,依次加入166mg无水硫酸铜和206mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到100mg化合物81,两步收率25.6%。
1H NMR(400Hz,DMSO-d6)δ8.16-8.18(m,2H),7.96-7.99(m,2H),7.65(dd,J=9.0,2.2Hz,1H),7.32(s,1H),6.54(s,1H),5.44(s,2H),5.34(s,2H),5.11(d,J=4.8Hz,1H),4.97(dd,J=15.2,4.8Hz,2H),4.52-4.57(m,5H),4.23(d,J=7.6Hz,1H),4.07-4.12(m,1H),3.89-3.92(m,1H),3.66-3.70(m,1H),3.54(t,J=6.0Hz,2H),3.40-3.46(m,1H),3.10-3.18(m,6H),2.94-3.06(m,2H),1.84-1.91(m,2H),1.75-1.80(m,2H),1.29(t,J=7.6Hz,3H),0.88(t,J=7.2Hz,3H)。
实施例15化合物87的合成
称量2.09g化合物82和5.6mL三乙胺溶于50mL二氯甲烷中,冷却至0℃,缓慢的滴加4.43g二碳酸二叔丁酯,滴加完毕后,室温反应过夜,反应液用1N HCl洗涤(100mL×3),有机层用无水硫酸钠干燥,过滤,浓缩得到4g化合物83,收率97.3%。
1H NMR(400Hz,CDCl3)δ4.56(s,1H),3.64(t,J=6.4Hz,2H),3.10-3.15(m,2H),1.27-1.61(m,15H)。
称量4g化合物83溶于60mL四氢呋喃中,加入812mg四丁基碘化铵,660mg碘化钠和3.92g 3-溴丙炔,室温搅拌下分小批量加入2.48g氢氧化钾,完毕后室温反应过夜,浓缩掉四氢呋喃,加入30mL水,乙酸乙酯萃取(30mL×3),有机层用无水硫酸钠干燥,过滤,浓缩柱层析得到2.8g化合物84,收率59.1%。
1H NMR(400Hz,CDCl3)δ4.54(s,1H),4.13(d,J=2.4Hz,2H),3.51(t,J=6.4Hz,2H),3.09-3.14(m,2H),2.42(t,J=2.4Hz,1H),1.58-1.63(m,2H),1.35-1.54(m,13H)。
称量2.8g化合物84溶于40mL甲醇中,加入40mL 3N HCl溶液,室温搅拌过夜,浓缩得到1.7g化合物85,收率86.7%。
1H NMR(400Hz,D2O)δ4.09(d,J=2.4Hz,2H),3.52(t,J=6.8Hz,2H),2.89(t,J=7.6Hz,2H),2.77(t,J=2.2Hz,1H),1.48-1.58(m,4H),1.24-1.36(m,2H)。
称量392mg化合物SN38溶于30mL DMF中,冷却至0℃,加入320mg DIPEA和266mg对硝基苯基氯甲酸酯,在此温度下继续反应半小时,室温反应3小时得到中间体64,然后加入320mg DIPEA和266mg化合物85。加入完毕后室温反应过夜,浓缩掉DMF,TLC监测反应良好。柱层析分离得到400mg粗品产物86。将200mg化合物86和200mg化合物32溶于16mL THF-H2O中,依次加入166mg无水硫酸铜和206mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到70mg化合物87,两步收率18.3%。
1H NMR(400Hz,DMSO-d6)δ8.29(s,1H),8.17(d,J=9.2Hz,1H),7.93-7.95(m,2H),7.64(dd,J=9.0,2.2Hz,1H),7.33(s,1H),6.51(s,1H),5.52(d,J=9.2Hz,1H),5.44(s,2H),5.36(d,J=6.0Hz,1H),5.33(s,2H),5.26(d,J=4.8Hz,1H),5.13(d,J=5.6Hz,1H),4.62(t,J=5.6Hz,1H),4.52(s,2H),3.68-3.78(m,2H),3.36-3.51(m,6H),3.20-3.25(m,2H),3.10-3.15(m,2H),1.85-1.92(m,2H),1.51-1.59(m,4H),1.36-1.42(m,2H),1.30(t,J=7.6Hz,3H),0.89(t,J=7.2Hz,3H)。
实施例16化合物88的合成
将200mg粗品化合物86和210mg化合物55溶于16mL THF-H2O中,依次加入166mg无水硫酸铜和206mg抗坏血酸钠,室温搅拌过夜,浓缩后柱层析分离得到70mg化合物88,两步收率17.3%。
1H NMR(400Hz,DMSO-d6)δ8.16(d,J=9.2Hz,1H),8.14(s,1H),7.91-7.94(m,2H),7.63(dd,J=9.2,2.4Hz,1H),7.32(s,1H),6.51(s,1H),5.44(s,2H),5.33(s,2H),5.06(d,J=4.8Hz,1H),4.93(dd,J=13.2,5.2Hz,2H),4.56(t,J=5.2Hz,2H),4.49-4.52(m,3H),4.23(d,J=8.0Hz,1H),4.07-4.08(m,1H),3.89-3.92(m,1H),3.65-3.67(m,1H),3.42-3.48(m,3H),3.09-3.20(m,6H),2.96-3.06(m,2H),1.86-1.89(m,2H),1.50-1.58(m,4H),1.34-1.38(m,2H),1.29(t,J=7.6Hz,3H),0.89(t,J=7.4Hz,3H)。
实施例17溶解度测定
溶解度实验采用平衡法,根据中华人民共和国药典2015版第四部0 4 0 1紫外-可见分光光度法,检测所得化合物在水、生理盐水、pH7.4的PBS及0.1%吐温80水溶液中的溶解度。称取适量化合物溶解至1mL甲醇溶液中,配制成一定浓度的对照品溶液,即C0。按下式计算供试品中被测溶液的浓度:CX=(AX/A0)C0;式中CX为供试品溶液的浓度;AX为供试品溶液的吸光度;C0为对照品溶液的浓度;A0为对照品溶液的吸光度。实验结果见表1。
表1化合物溶解度试验结果
由表1结果可知,SN38在水、生理盐水、pH7.4的PBS及0.1%吐温80水溶液中的溶解度均非常低。通过结构改造后,所得化合物溶解度比SN38大大提高,且大部分化合物在生理盐水中的溶解度显著高于或接近CPT-11。
实施例18细胞毒性试验
为了考察所得化合物的抗肿瘤活性,我们选择了多种肿瘤细胞株进行试验。取对数生长的细胞,接种于96孔板中过夜,然后加入一定梯度浓度的药物,置于细胞培养箱(5%CO2,37℃)孵育72h,采用MTT法进行药效评价,考察药物对不同细胞的半数生长抑制浓度IC50值,以CPT-11作为对照。评价结果见表2。根据体外实验结果,在所测试的肿瘤细胞株中,合成的SN38衍生物均显示出优异的抗肿瘤活性,且对大部分肿瘤的生长抑制作用强于CPT-11。
表2体外细胞毒性试验结果
实施例19体内抗肿瘤活性研究
综合考虑溶解性和体外细胞毒性结果,我们对化合物58和67的体内抗肿瘤活性进行研究。步骤如下:
将4~5周龄的Balb/c小鼠饲养于无特定病原体(SPF)的环境中。饲养一周后,在小鼠皮下接种结肠癌细胞SW-480,接种密度为1.0×107个每只,待肿瘤长至约100mm3后,随机分成4组:生理盐水对照组(Control组)、盐酸伊立替康组(CPT-11组,15mg/kg即0.024mmol/kg)、化合物58组(13.73mg/kg即0.016mmol/kg)、化合物67组(12.30mg/kg即0.016mmol/kg),给药方式为将化合物溶解于生理盐水,静脉注射,每三天给药一次,连续给药7次。每三天测量一次肿瘤大小和体积,直至给药完成。实验结束后,断颈处死裸鼠,对裸鼠进行解剖,取重要脏器保存待用。
表3和表4分别是小鼠肿瘤体积-时间变化数据和小鼠体重-时间变化数据,图1和图2分别是小鼠肿瘤体积-时间变化图和小鼠体重-时间变化图。根据表3和图1,化合物58和67在剂量为CPT-11摩尔数的三分之二时,对结肠癌细胞SW-480的抑制率均显著大于CPT-11。根据表4和图2,在给药剂量下,没有引起小鼠体重下降,表明化合物在给药剂量下没有表现出明显的毒性。
表3裸鼠肿瘤体积-时间变化数据(平均值,n=6)
表4裸鼠体重-时间变化数据
综上所述,通过对SN38的结构进行改造,大大增加了SN38的水溶性,体内外实验结果表明,所得衍生物抗肿瘤活性优于盐酸伊立替康。
实施例20多剂量体内抗肿瘤活性研究
试验分组及治疗方案
将接种成功的小鼠随机分成8组,每组6只:生理盐水组(NS)、CPT-11组、化合物58低剂量组、化合物58中剂量组、化合物58高剂量组、化合物67低剂量组、化合物67中剂量组和化合物67高剂量组。通过小鼠尾静脉给药,每隔2天给药一次,共给药7次。
给药剂量为CPT-11组:10mg/kg;化合物58和67的高、中、低剂量组,分别与伊立替康的摩尔比为1/1、1/2和1/4,即化合物58高剂量组(H):13.73mg/kg,化合物58中剂量组(M):6.865mg/kg、化合物58低剂量组(L):3.433mg/kg;化合物67高剂量组(H):12.30mg/kg、化合物67中剂量组(M):6.15mg/kg、化合物67低剂量组(L):3.075mg/kg。
从0天起,每隔2天测量1次肿瘤体积,先测量肿瘤的最大径(a),再测量与最大径线垂直的最长径线(b),单位为mm,按以下公式,计算肿瘤体积:
治疗周期结束后,取小鼠眼眶静脉血用于后期的血常规检测,随后采用颈椎脱臼法处死小鼠,立即剥除肿瘤,拍照。从第0天起,每隔2天称量并记录各组小鼠体重,计算各组体重平均值,根据统计数据绘小鼠体重变化曲线。待治疗周期结束后,麻醉小鼠,立即剥除肿瘤,称量并记录各组肿瘤重量,计算各组肿瘤瘤重平均值,根据以下公式计算肿瘤抑制率(%):
然后摘取小鼠的心、肝、脾、肺、肾,以备后期脏器的H&E染色以及肿瘤组织的免疫组化。以时间为横坐标,肿瘤体积为纵坐标绘制肿瘤体积生长变化曲线;以时间为横坐标,小鼠体重为纵坐标绘制小鼠体重变化曲线。肿瘤体积生长变化和裸鼠体重时间变化见图表5和表6。肿瘤体积生长变化曲线和裸鼠体重时间变化见图3-5。
由表5和图3,4肿瘤体积生长曲线可知,化合物58和化合物67对肿瘤的抑制均具有剂量依耐性,末次给药后各治疗组与对照组相比均存在统计学差异(p<0.05)。化合物58和化合物67高剂量组在同等给药剂量下(10mg/kg)肿瘤抑制效果强于阳性对照组CPT-11组(p<0.001),其中,化合物58高剂量组肿瘤体积增长最缓慢,且末次给药后的肿瘤体积与其他制剂组均具有显著性差异(p<0.001),说明该制剂组抑瘤药效果最强。由表6和图5可得,各剂量组药物均未对小鼠体重产生影响,表明化合物具有较高的安全性。
表5多剂量化合物58和化合物67的体内抗肿瘤活性研究肿瘤体积-时间变化数据
表6多剂量化合物体内抗肿瘤活性研究中体重时间变化数据
Claims (31)
1.喜树碱衍生物,其特征在于,所述的喜树碱衍生物由式1所示的物质经糖基化三氮唑在R3位置修饰而成;所述式1所示的结构式中R1代表H、C1-10的烷基、C1-10的氘代烷基或C1-C10的卤代烷基;R2代表H、CH2N(CH3)2或CH2N(CD3)2;R4代表或H,其中X代表N,O或S;L代表多肽、C1-20直链烷基或其衍生物、C1-20直链或支链酰基衍生物、C2-100乙二醇或其衍生物,
8.根据权利要求6或7所述的喜树碱衍生物,其特征在于,所述a或所述b为1-20的整数。
11.根据权利要求10所述的喜树碱衍生物,其特征在于,所述X选自N或O。
12.根据权利要求10所述的喜树碱衍生物,其特征在于,所述Y为
13.根据权利要求12所述的喜树碱衍生物,其特征在于,所述d为0-1的整数。
14.根据权利要求8所述的喜树碱衍生物,其特征在于,所述a为1,b为1-4的整数。
18.根据权利要求17所述的方法,其特征在于,所述R5的结构式如式5-28任一所示。
19.根据权利要求18所述的方法,其特征在于,所述R5选自单糖残基式5、6、18和19中的任一。
20.根据权利要求17所述的方法,其特征在于,所述a为1,b为1-4的整数。
22.根据权利要求21所述的方法,其特征在于,所述d为0-1的整数。
23.肿瘤细胞生长抑制剂,其特征在于,所述抑制剂由权利要求1-14任一项所述的喜树碱衍生物制备而成。
24.根据权利要求23所述的肿瘤细胞生长抑制剂,其特征在于,所述肿瘤细胞生长抑制剂可通过和拓扑异构酶I、DNA形成三元复合物使DNA链断裂,抑制肿瘤细生长和促进肿瘤细胞凋亡。
25.根据权利要求23或24所述的肿瘤细胞生长抑制剂,其特征在于,所述肿瘤为结直肠瘤、肺瘤和乳腺瘤、肝癌、胃癌、食管癌、白血病、前列腺癌、骨肉瘤、宫颈癌、甲状腺癌、卵巢癌或胰腺癌。
26.三元复合物,其特征在于,由权利要求22-24任一项所述的肿瘤细胞生长抑制剂通过和拓扑异构酶I、DNA形成所述的三元复合物。
27.权利要求1-14任一项所述的喜树碱衍生物在制备抗癌药物中的应用。
28.根据权利要求27所述的应用,其特征在于,所述癌为结直肠癌、肺癌和乳腺癌、肝癌、胃癌、食管癌、白血病、前列腺癌、骨肉瘤、宫颈癌、甲状腺癌、卵巢癌或胰腺癌。
29.根据权利要求27所述的应用,其特征在于,所述抗癌药物可通过和拓扑异构酶I、DNA形成三元复合物使DNA链断裂,抑制肿瘤细生长和促进肿瘤细胞凋亡以达到抗癌作用,所述肿瘤细胞为SW-480和/或HT-29和/或HCT-116和/或A549和/或H1975和/或HepG2和/或BGC-823和/或ECA-109和/或K562和/或PC3和/或143B和/或MDA-MB-231和/或Hela和/或TPC-1和/或SKOV-3和/或PANC-1。
30.权利要求1-14任一项所述的喜树碱衍生物制备的制剂。
31.根据权利要求30所述的制剂,其特征在于,所述制剂中含有药学可接受载体和/或助剂。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810951933 | 2018-08-21 | ||
CN2018109519337 | 2018-08-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110845559A true CN110845559A (zh) | 2020-02-28 |
CN110845559B CN110845559B (zh) | 2023-02-28 |
Family
ID=69592246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910752828.5A Active CN110845559B (zh) | 2018-08-21 | 2019-08-15 | 新型喜树碱衍生物及其制备方法和应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11572382B2 (zh) |
CN (1) | CN110845559B (zh) |
WO (1) | WO2020038278A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007052308A2 (en) * | 2005-11-03 | 2007-05-10 | Brain N' Beyond Biotech Pvt. Ltd. | Glyco-phosphorylated biologically active agents |
US20080166363A1 (en) * | 2002-12-13 | 2008-07-10 | Immunomedics, Inc. | Camptothecin-Binding Moiety Conjugates |
US20120171227A1 (en) * | 2009-06-30 | 2012-07-05 | The Regents Of The University Of Michigan | Pro-drug complexes and related methods of use |
CN104837508A (zh) * | 2012-12-13 | 2015-08-12 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量 |
US20180021446A1 (en) * | 2014-08-14 | 2018-01-25 | Mamoun M. Alhamadsheh | Systems for stabilizing and delivering active agents |
CN107735090A (zh) * | 2012-12-13 | 2018-02-23 | 免疫医疗公司 | 具有cl2a接头的抗体‑sn‑38免疫缀合物 |
WO2019008441A1 (en) * | 2017-07-04 | 2019-01-10 | Intocell, Inc. | COMPOUNDS COMPRISING A CLIABABLE BIT AND USES THEREOF |
-
2019
- 2019-08-15 US US17/270,063 patent/US11572382B2/en active Active
- 2019-08-15 WO PCT/CN2019/100802 patent/WO2020038278A1/zh active Application Filing
- 2019-08-15 CN CN201910752828.5A patent/CN110845559B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080166363A1 (en) * | 2002-12-13 | 2008-07-10 | Immunomedics, Inc. | Camptothecin-Binding Moiety Conjugates |
WO2007052308A2 (en) * | 2005-11-03 | 2007-05-10 | Brain N' Beyond Biotech Pvt. Ltd. | Glyco-phosphorylated biologically active agents |
US20120171227A1 (en) * | 2009-06-30 | 2012-07-05 | The Regents Of The University Of Michigan | Pro-drug complexes and related methods of use |
CN104837508A (zh) * | 2012-12-13 | 2015-08-12 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量 |
CN107735090A (zh) * | 2012-12-13 | 2018-02-23 | 免疫医疗公司 | 具有cl2a接头的抗体‑sn‑38免疫缀合物 |
US20180021446A1 (en) * | 2014-08-14 | 2018-01-25 | Mamoun M. Alhamadsheh | Systems for stabilizing and delivering active agents |
WO2019008441A1 (en) * | 2017-07-04 | 2019-01-10 | Intocell, Inc. | COMPOUNDS COMPRISING A CLIABABLE BIT AND USES THEREOF |
Also Published As
Publication number | Publication date |
---|---|
US20210246157A1 (en) | 2021-08-12 |
CN110845559B (zh) | 2023-02-28 |
US11572382B2 (en) | 2023-02-07 |
WO2020038278A1 (zh) | 2020-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2880029T3 (es) | Derivados de anfotericina B | |
RU2450008C2 (ru) | Производные камптотецина с противоопухолевой активностью | |
CA2951516C (en) | Polyene macrolide derivative | |
JPS59108786A (ja) | ブリオスタチン類 | |
JPH05508619A (ja) | ヒト結腸直腸癌の有効な抑制剤であるカンプトセシンアナローグ | |
WO2012175002A1 (zh) | 10-甲氧基喜树碱衍生物、制备方法和用途 | |
JPS61501986A (ja) | パンクラチスタチン | |
RU2411244C2 (ru) | Производные камптотецина и их применение | |
JPH08337584A (ja) | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 | |
CN105732659B (zh) | 硝基咪唑类化合物及其制备方法和在制药中的用途 | |
CN110845559B (zh) | 新型喜树碱衍生物及其制备方法和应用 | |
CN110152013B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
JPH035494A (ja) | 二量体エピポドフィロトキシングルコシド誘導体 | |
WO2007140239A1 (en) | Crystalline form of 5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin | |
RU2450007C2 (ru) | Производные камптотецина с противоопухолевой активностью | |
CN110418653B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
CN110903289B (zh) | 嘌呤-氨甲基-吡啶酮衍生物及其制备方法和用途 | |
CN102167812B (zh) | 聚乙二醇化环巴胺类似物及其制备方法和用途 | |
CN101402640B (zh) | 双酯化喜树碱衍生物及其制备方法和应用 | |
WO2024175069A1 (zh) | 喜树碱衍生物及其偶联物以及其制备方法和医药用途 | |
EP2699580B1 (en) | Diazonamide analogs | |
CN117700419A (zh) | 一氧化氮供体型咔唑衍生物及其在治疗肿瘤疾病中的用途 | |
WO2023274313A1 (zh) | 两性霉素b半合成衍生物及其制备方法和用途 | |
CN118056834A (zh) | 稠环吡啶酮衍生物及其制备方法和用途 | |
CN118047811A (zh) | 一种抗流感病毒磷酸酯类化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220914 Address after: Room 1201, 12th Floor, Building 1, No. 666, Jinfu Road, Jinniu District, Chengdu, Sichuan 610000 Applicant after: SICHUAN FUSHENGYUAN TECHNOLOGY Co.,Ltd. Address before: Room 101, Sunshine World Garden, No. 6, Longwei Road, Longwei Community, Meilin Street, Futian District, Shenzhen, Guangdong 518049 Applicant before: Shenzhen target biomedical technology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |